Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

Subjects:

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

Subjects:

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

Subjects:

(a) Histogram of relative phase at all steps for all participants. by Shinnosuke Hase (20917896)

Data Sheet 1_Eupalinolide A inhibits cancer progression and induces ferroptosis and apoptosis by targeting the AMPK/mTOR/SCD1 signalling in non-small cell lung cancer.docx by Yonghui Zhang (279832)

“…EA treatment (25 mg/kg) markedly inhibited tumour growth in vivo in a xenograft model; both tumour weight and tumour volume decreased by more than 60% without significantly affecting the body weight of tumour-bearing mice.…”

Correlation analysis, Data show only the values of the correlations that were significant (p < 0.05). by Glaucia Vilar-Pereira (686134)

BFD2 aggravates the inflammatory response to <i>Toxoplasma gondii</i> infection. by Xiaocheng Zhang (3140460)

Subjects:

Age-standardized prevalence rates of gynecological diseases across 21 GBD regions, by SDI, from 1990 to 2021. by Xiaofeng He (2618752)

Subjects:

Conceptual framework to guide the study. by Resham B. Khatri (10949429)

Subjects:

Basic characteristics of the studies included. by Renáta Kiss-Miki (20760127)

Subjects:

List_of_studies_identified_31-JAN-2025. by Renáta Kiss-Miki (20760127)

Subjects:

Data_extraction_table_31-JAN-2025. by Renáta Kiss-Miki (20760127)

Subjects:

Effect of DM, and/or <i>M. charantia</i> on the (I) number of corpuses lutea; (II) number of neonates, (III) weight of neonates; (IV) length of neonates levels in the control and d... by Amoura M. Abou-El-Naga (21001524)

Age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. by Xiaofeng He (2618752)

Subjects:

Estimated annual percentage change in age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. by Xiaofeng He (2618752)

Subjects:

Estimated annual percentage changes in the prevalence rate of specific gynecological diseases from 1990 to 2021, categorized by age group and SDI. by Xiaofeng He (2618752)

Subjects:

Effect of DM, and/or <i>M. charantia</i> on the (I) glucose; (II) HOMA IR, (III) QUICKI levels; (IV) GLUT4; (V) AMPK; (VI) insulin; (VII) leptin levels in the control and different... by Amoura M. Abou-El-Naga (21001524)

Effect of DM, and/or <i>M. charantia</i> on the neurotransmitters levels, acetylcholine (I) and dopamine (II). by Amoura M. Abou-El-Naga (21001524)

The prevalence and absolute counts of peripheral blood Lymphocyte subsets. by Songyan Zou (11399489)

Subjects:

Prevalence and trends of gynecological diseases (GDs) among women of childbearing age, by age group and SDI. by Xiaofeng He (2618752)

Subjects: